Publications

1. Dela Cruz FS, Stewart EA, Surdez D, Daley JD, Soragni A, Tomazou EM, Alvarez-Perez J, Feinberg TY, Amatruda JF, Ganapathi SS, Ohm JE, Heske CM, Cohen-Gogo S, Pesic D, Nash JO, Shlien A, Roundhill EA, Burchill SA, Crompton BD, Lawlor ER, Loeb DM, Delattre O, Mora J, Scotlandi K, Reed DR, Grohar PJ, Grünewald TGP, Kovar H, Bailey KM. Advancing preclinical biology for Ewing Sarcoma: an international effort.. Molecular cancer therapeutics, 2025.
2. Wang X, Calucho M, Estrada-Zuniga CM, Noureen M, Gonzalez-Cantu H, Mossuto S, Levi JN, Landry B, Guo Q, Rutherford KA, Cheng ZM, Sannajust A, Raghunathan S, Balaji S, da Conceicao VN, Norris S, Munawar SY, Nguyen HT, De Rosa J, Tomlinson G, Wu JX, Yeh MW, Livhits MJ, Vaidya A, Powers J, Lechan R, Tischler A, Zhang M, Graham P, Jimenez C, Peitzsch M, Bechmann N, Eisenhofer G, Ding Y, Kitano M, Soragni A, Dahia PLM. Patient-derived organoids reveal hypoxia-driven plasticity and therapeutic vulnerabilities in pheochromocytomas and paragangliomas.. bioRxiv : the preprint server for biology, 2025.
3. Iyer R, Deshpande A, Pedgaonkar A, Bala PA, Kim T, Brien GL, Finlay D, Vuori K, Soragni A, Wetterstein HI, Murad R, Deshpande AJ. Targeting SUMO2 reverses aberrant epigenetic rewiring driven by SS18::SSX fusion oncoproteins and impairs sarcomagenesis.. The EMBO journal, 2025.
4. Daley JD, Whiteway SL, Heske CM, Dela Cruz FS, Whittle SB, Cohen-Gogo S, Collier AB, Gupta A, Ohm J, Clark A, Soragni A, Lawlor E, Setty B, Grohar PJ, Janeway K, Reed DR, Slotkin EK, Bailey KM. New Approaches to Investigate Novel Agents in Ewing Sarcoma: A Report From the Children's Oncology Group Bone Tumor Committee.. Pediatric blood & cancer, 2025.
5. Crane JN, Douglass DP, Oberoi S, Collins NB, Gupta A, Metts JL, Avutu V, Dela Cruz FS, Davis JL, Federman NC, Hiniker SM, Laetsch TW, Linardic CM, Navid F, Saab R, Shulman DS, Shern JF, Soragni A, Stewart EA, Terezakis S, Weigel BJ, Weiss AR. Prioritization of novel agents for further investigation in pediatric non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children's Oncology Group.. European journal of cancer (Oxford, England : 1990), 2025.
6. Soragni A, Knudsen ES, O'Connor TN, Tognon CE, Tyner JW, Gini B, Kim D, Bivona TG, Zang X, Witkiewicz AK, Goodrich DW, Jiang D, Gammon ST, Willey CD, Boutros PC, Sandulache VC, Osman AA, Myers JN, Mehla K, Singh PK, Chan KS, Gao H, Marathe H, National Cancer Institute (NCI) Acquired Resistance to Therapy Network (ARTNet). Acquired resistance in cancer: towards targeted therapeutic strategies.. Nature reviews. Cancer, 2025.
7. Zhao H, Park YM, Zheng Y, Mao Q, Collet C, Hu B, Zhou T, Lin L, Wong S, Pan Y, Monreal AV, Sinha UK, Sedghizadeh P, Soragni A, Lin DC. Genetically Defined Organoid Models Reveal Mechanisms Driving Squamous Cell Neoplastic Evolution and Identify Potential Therapeutic Vulnerabilities.. bioRxiv : the preprint server for biology, 2025.
8. Iyer R, Deshpande A, Pedgaonkar A, Bala PA, Kim T, Brien GL, Finlay D, Vuori K, Soragni A, Murad R, Deshpande AJ. SUMO2 Inhibition Reverses Aberrant Epigenetic Rewiring Driven by Synovial Sarcoma Fusion Oncoproteins and Impairs Sarcomagenesis.. bioRxiv : the preprint server for biology, 2024.
9. Al Shihabi A, Tebon PJ, Nguyen HTL, Chantharasamee J, Sartini S, Davarifar A, Jensen AY, Diaz-Infante M, Cox H, Gonzalez AE, Norris S, Sperry J, Nakashima J, Tavanaie N, Winata H, Fitz-Gibbon ST, Yamaguchi TN, Jeong JH, Dry S, Singh AS, Chmielowski B, Crompton JG, Kalbasi AK, Eilber FC, Hornicek F, Bernthal NM, Nelson SD, Boutros PC, Federman NC, Yanagawa J, Soragni A. The landscape of drug sensitivity and resistance in sarcoma.. Cell stem cell, 2024.
10. Sartini S, Omholt L, Moatamed NA, Soragni A. Mutant p53 Misfolding and Aggregation Precedes Transformation into High-Grade Serous Ovarian Carcinoma.. bioRxiv : the preprint server for biology, 2024.
11. Metts JL, Aye JM, Crane JN, Oberoi S, Balis FM, Bhatia S, Bona K, Carleton B, Dasgupta R, Dela Cruz FS, Greenzang KA, Kaufman JL, Linardic CM, Parsons SK, Robertson-Tessi M, Rudzinski ER, Soragni A, Stewart E, Weigel BJ, Wolden SL, Weiss AR, Venkatramani R, Heske CM. Roadmap for the next generation of Children's Oncology Group rhabdomyosarcoma trials.. Cancer, 2024.
12. Nguyen HTL, Kohl E, Bade J, Eng SE, Tosevska A, Al Shihabi A, Tebon PJ, Hong JJ, Dry S, Boutros PC, Panossian A, Gosline SJC, Soragni A. A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.. Cell reports methods, 2024.
13. Gigon L, Müller P, Haenni B, Iacovache I, Barbo M, Gosheva G, Yousefi S, Soragni A, von Ballmoos C, Zuber B, Simon HU. Membrane damage by MBP-1 is mediated by pore formation and amplified by mtDNA.. Cell reports, 2024.
14. Tebon PJ, Wang B, Markowitz AL, Davarifar A, Tsai BL, Krawczuk P, Gonzalez AE, Sartini S, Murray GF, Nguyen HTL, Tavanaie N, Nguyen TL, Boutros PC, Teitell MA, Soragni A. Drug screening at single-organoid resolution via bioprinting and interferometry.. Nature communications, 2023.
15. Zhao Z, Chen X, Dowbaj AM, Sljukic A, Bratlie K, Lin L, Fong ELS, Balachander GM, Chen Z, Soragni A, Huch M, Zeng YA, Wang Q, Yu H. Organoids.. Nature reviews. Methods primers, 2022.
16. Al Shihabi A, Davarifar A, Nguyen HTL, Tavanaie N, Nelson SD, Yanagawa J, Federman N, Bernthal N, Hornicek F, Soragni A. Personalized chordoma organoids for drug discovery studies.. Science advances, 2022.
17. Sartini S, Soragni A. Cervical organoids go viral.. Cell stem cell, 2021.
18. Nguyen HTL, Soragni A. Patient-Derived Tumor Organoid Rings for Histologic Characterization and High-Throughput Screening.. STAR protocols, 2020.
19. Soragni A, Maitra A. Of scientists and tweets.. Nature reviews. Cancer, 2019.
20. Phan N, Hong JJ, Tofig B, Mapua M, Elashoff D, Moatamed NA, Huang J, Memarzadeh S, Damoiseaux R, Soragni A. A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids.. Communications biology, 2019.
21. Avasthi P, Soragni A, Bembenek JN. Journal clubs in the time of preprints.. eLife, 2018.
22. Soragni A, Janzen DM, Johnson LM, Lindgren AG, Thai-Quynh Nguyen A, Tiourin E, Soriaga AB, Lu J, Jiang L, Faull KF, Pellegrini M, Memarzadeh S, Eisenberg DS. A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas.. Cancer cell, 2015.
23. Soragni A, Yousefi S, Stoeckle C, Soriaga AB, Sawaya MR, Kozlowski E, Schmid I, Radonjic-Hoesli S, Boutet S, Williams GJ, Messerschmidt M, Seibert MM, Cascio D, Zatsepin NA, Burghammer M, Riekel C, Colletier JP, Riek R, Eisenberg DS, Simon HU. Toxicity of eosinophil MBP is repressed by intracellular crystallization and promoted by extracellular aggregation.. Molecular cell, 2015.
24. Ries J, Udayar V, Soragni A, Hornemann S, Nilsson KP, Riek R, Hock C, Ewers H, Aguzzi AA, Rajendran L. Superresolution imaging of amyloid fibrils with binding-activated probes.. ACS chemical neuroscience, 2013.
25. Rabe M, Soragni A, Reynolds NP, Verdes D, Liverani E, Riek R, Seeger S. On-surface aggregation of α-synuclein at nanomolar concentrations results in two distinct growth mechanisms.. ACS chemical neuroscience, 2013.
26. Reynolds NP, Soragni A, Rabe M, Verdes D, Liverani E, Handschin S, Riek R, Seeger S. Mechanism of membrane interaction and disruption by α-synuclein.. Journal of the American Chemical Society, 2011.
27. Schütz AK, Soragni A, Hornemann S, Aguzzi A, Ernst M, Böckmann A, Meier BH. The amyloid-Congo red interface at atomic resolution.. Angewandte Chemie (International ed. in English), 2011.
28. Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, Hetzer C, Loher T, Vilar M, Campioni S, Tzitzilonis C, Soragni A, Jessberger S, Mira H, Consiglio A, Pham E, Masliah E, Gage FH, Riek R. In vivo demonstration that alpha-synuclein oligomers are toxic.. Proceedings of the National Academy of Sciences of the United States of America, 2011.
29. Wasmer C, Zimmer A, Sabaté R, Soragni A, Saupe SJ, Ritter C, Meier BH. Structural similarity between the prion domain of HET-s and a homologue can explain amyloid cross-seeding in spite of limited sequence identity.. Journal of molecular biology, 2010.
30. Greenwald J, Buhtz C, Ritter C, Kwiatkowski W, Choe S, Maddelein ML, Ness F, Cescau S, Soragni A, Leitz D, Saupe SJ, Riek R. The mechanism of prion inhibition by HET-S.. Molecular cell, 2010.
31. Lange A, Gattin Z, Van Melckebeke H, Wasmer C, Soragni A, van Gunsteren WF, Meier BH. A combined solid-state NMR and MD characterization of the stability and dynamics of the HET-s(218-289) prion in its amyloid conformation.. Chembiochem : a European journal of chemical biology, 2009.
32. Soragni A, Zambelli B, Mukrasch MD, Biernat J, Jeganathan S, Griesinger C, Ciurli S, Mandelkow E, Zweckstetter M. Structural characterization of binding of Cu(II) to tau protein.. Biochemistry, 2008.
33. Wasmer C, Soragni A, Sabaté R, Lange A, Riek R, Meier BH. Infectious and noninfectious amyloids of the HET-s(218-289) prion have different NMR spectra.. Angewandte Chemie (International ed. in English), 2008.
34. Aachmann FL, Fomenko DE, Soragni A, Gladyshev VN, Dikiy A. Solution structure of selenoprotein W and NMR analysis of its interaction with 14-3-3 proteins.. The Journal of biological chemistry, 2007.
35. Delany I, Ieva R, Soragni A, Hilleringmann M, Rappuoli R, Scarlato V. In vitro analysis of protein-operator interactions of the NikR and fur metal-responsive regulators of coregulated genes in Helicobacter pylori.. Journal of bacteriology, 2005.